Oncology News and Research

RSS
Special CD4+ T cells appear to inhibit cancer growth, enhance tumor-killing powers of other immune cells

Special CD4+ T cells appear to inhibit cancer growth, enhance tumor-killing powers of other immune cells

UM SOM researchers to initiate first clinical trial of GammaPod system in patients with early-stage breast cancer

UM SOM researchers to initiate first clinical trial of GammaPod system in patients with early-stage breast cancer

Study reveals gene mutation that increases risk of SUDEP in patients with mild forms of disease

Study reveals gene mutation that increases risk of SUDEP in patients with mild forms of disease

Rare genetic mutation could improve outcomes in NSCLC patients with brain metastases

Rare genetic mutation could improve outcomes in NSCLC patients with brain metastases

Study suggests combination of MMF and CNIs can protect against rare lymphoma

Study suggests combination of MMF and CNIs can protect against rare lymphoma

Study shows why cancer anemia therapy stimulates tumor growth

Study shows why cancer anemia therapy stimulates tumor growth

Study finds link between microbial signatures and triple negative breast cancer

Study finds link between microbial signatures and triple negative breast cancer

Study reveals high rates of preventable cancers in Indigenous peoples of high-income countries

Study reveals high rates of preventable cancers in Indigenous peoples of high-income countries

Specific gene signature could help predict survival outcomes among children with intermediate-risk RMS

Specific gene signature could help predict survival outcomes among children with intermediate-risk RMS

Novel ligand peptide-mimic inhibits abnormal overgrowth of blood vessels, may lead to new anti-cancer drugs

Novel ligand peptide-mimic inhibits abnormal overgrowth of blood vessels, may lead to new anti-cancer drugs

Researchers link organ transplant drug to rise in rare lymphoma

Researchers link organ transplant drug to rise in rare lymphoma

OncoSec reports net loss of $6.5 million for fourth quarter of fiscal 2015

OncoSec reports net loss of $6.5 million for fourth quarter of fiscal 2015

CU Cancer Center study reports 'robust antitumor activity' of TAK-733 drug in mouse models of colorectal cancer

CU Cancer Center study reports 'robust antitumor activity' of TAK-733 drug in mouse models of colorectal cancer

Brain areas linked to social behaviors underdeveloped in youths with high functioning ASD

Brain areas linked to social behaviors underdeveloped in youths with high functioning ASD

Blocking the production of CHD4 protein may help increase effectiveness of AML treatments

Blocking the production of CHD4 protein may help increase effectiveness of AML treatments

Lilly, ImaginAb partner to study potential novel T-cell-based immuno-oncology therapies

Lilly, ImaginAb partner to study potential novel T-cell-based immuno-oncology therapies

Quest Diagnostics provides Dako’s PD-L1 complementary diagnostic test for non-squamous non-small cell carcinoma

Quest Diagnostics provides Dako’s PD-L1 complementary diagnostic test for non-squamous non-small cell carcinoma

Elekta’s high field MRI-guided linear accelerator installed at MD Anderson Cancer Center

Elekta’s high field MRI-guided linear accelerator installed at MD Anderson Cancer Center

Gensignia gets CLIA certification to establish clinical laboratory in San Diego

Gensignia gets CLIA certification to establish clinical laboratory in San Diego

Study highlights need for dietary interventions in cancer survivors

Study highlights need for dietary interventions in cancer survivors

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.